IgG Glycans Confirmed as Aging Biomarker With Plasma Exchange Cutting Biological Age Fastest
A 20,000-person study validates IgG glycans as aging biomarkers, with therapeutic plasma exchange reducing glycan age by 0.4 years per month.
Summary
A large preprint study combining data from over 20,000 people across 42 studies has validated IgG glycans — sugar molecules attached to immune proteins — as a reliable biological aging marker. Researchers found that glycan patterns independently predict all-cause mortality and respond to interventions. Three anti-aging approaches were compared: therapeutic plasma exchange (TPE), hormone replacement therapy, and caloric restriction. TPE produced the biggest monthly reduction in biological age, cutting glycan age by 0.4 years per month. Earlier clinical data also showed that biweekly TPE combined with intravenous immunoglobulin reduced biological age by 2.6 years on average across multiple aging measures. The findings position IgG glycans as both a predictor of health outcomes and a tool for tracking whether interventions are actually working.
Detailed Summary
Measuring biological age accurately is one of longevity science's biggest challenges. A new large-scale preprint may offer a significant step forward by validating IgG glycans — sugar chains on immune antibodies — as a robust aging biomarker that also responds to treatment. This matters because a biomarker that tracks intervention effectiveness could accelerate how quickly researchers and clinicians identify what actually slows aging.
The study pooled IgG N-glycome data from 20,405 individuals across 42 independent studies conducted between 2008 and 2025. Led by Professor Gordan Lauc and co-authored by researchers from the Buck Institute, King's College London, and the University of Freiburg, the analysis found that glycan patterns independently predict all-cause mortality — meaning they carry predictive value beyond standard risk factors.
Three geroprotective interventions were evaluated for their impact on glycan age. Therapeutic plasma exchange produced the largest reduction at minus 0.4 years per month. Hormone replacement therapy and caloric restriction also showed reductions, though smaller. Separately, earlier randomized data from Circulate Health showed biweekly TPE combined with intravenous immunoglobulin reduced biological age by an average of 2.6 years across a multi-omics panel.
The researchers frame glycan patterns as a mechanistic link among chronic inflammation, disease risk, and aging — suggesting glycans don't just track aging passively but may reflect underlying inflammatory biology driving it. The study claims to meet the Biomarkers of Aging Consortium's validation criteria, lending it additional credibility.
Important caveats apply. This is a preprint and has not yet completed peer review. The study was announced by GlycanAge and Circulate Health, companies with commercial interests in glycan testing and TPE services respectively, introducing potential bias. TPE remains expensive, specialist, and not widely accessible, so while the findings are promising, independent replication and peer review are essential before clinical recommendations change.
Key Findings
- IgG glycans independently predict all-cause mortality across 20,405 individuals in 42 studies
- Therapeutic plasma exchange reduced glycan biological age by 0.4 years per month, the largest effect observed
- Biweekly TPE plus intravenous immunoglobulin reduced multi-omics biological age by an average of 2.6 years
- Glycans link chronic inflammation to disease risk, acting as both mechanistic and predictive aging markers
- Study claims to meet Biomarkers of Aging Consortium criteria, positioning glycans as a validated aging clock
Methodology
This is a news report summarizing a company-issued preprint announcement from GlycanAge and Circulate Health. The underlying study integrates data from 42 independent cohorts totaling over 20,000 individuals, lending statistical scale, but peer review is pending. Commercial involvement from companies with financial interests in glycan testing and TPE introduces potential bias that warrants scrutiny.
Study Limitations
The study is a preprint and has not been peer-reviewed, so findings should be treated as preliminary. Both announcing companies — GlycanAge and Circulate Health — have direct commercial stakes in glycan biomarkers and TPE services, creating conflict-of-interest risk. Independent replication of TPE effect sizes and longer-term outcome data are needed before clinical translation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.